Mannkind Corp Sample Contracts

EXHIBIT 1.1 UNDERWRITING AGREEMENT
Mannkind Corp • April 30th, 2004 • New York
Sample 1Sample 2Sample 3See All (1k)
AutoNDA by SimpleDocs
RECITALS
Registration Rights Agreement • April 30th, 2004 • Mannkind Corp • California
Sample 1Sample 2Sample 3See All (740)
Exhibit 10.15 SUPPLY AGREEMENT THIS AGREEMENT is made this 1st day of January, 2000 by and between DIOSYNTH B.V., having its registered office at Kloosterstraat 6, 5349 AB Oss, the Netherlands (hereinafter referred to as "Diosynth"), and...
Supply Agreement • July 27th, 2004 • Mannkind Corp • Pharmaceutical preparations • England
Sample 1Sample 2Sample 3See All (610)
RECITALS
Indemnity Agreement • April 30th, 2004 • Mannkind Corp • Delaware
Sample 1Sample 2Sample 3See All (534)
Exhibit 10.10 MANNKIND CORPORATION CHANGE OF CONTROL AGREEMENT This Change of Control Agreement (this "Agreement"), dated and effective as of August 1, 2003, is between MannKind Corporation, a Delaware corporation (the "Company"), and Wendell Cheatham...
Change of Control Agreement • April 30th, 2004 • Mannkind Corp • California
Sample 1Sample 2Sample 3See All (502)
COMMON STOCK PURCHASE WARRANT MANNKIND CORPORATION
Common Stock Purchase Warrant • December 21st, 2018 • Mannkind Corp • Pharmaceutical preparations • New York

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant” and the term “Warrants” below refers to this Warrant and all other warrants to purchase Common Stock originally issued by the Company on the date hereof) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on December [26], 2019 (the “Termination Date”) but not thereafter, to subscribe for and purchase from MannKind Corporation, a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Sample 1Sample 2Sample 3See All (489)
SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • May 10th, 2016 • Mannkind Corp • Pharmaceutical preparations • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of May 9, 2016, between MannKind Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

Sample 1Sample 2Sample 3See All (480)
MANNKIND CORPORATION AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of March 4, 2021 2.50% Convertible Senior Notes due 2026
Indenture • March 5th, 2021 • Mannkind Corp • Pharmaceutical preparations • New York

INDENTURE dated as of March 4, 2021 between MANNKIND CORPORATION, a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee,” as more fully set forth in Section 1.01).

Sample 1Sample 2Sample 3See All (447)
Controlled Equity OfferingSM Sales Agreement
Mannkind Corp • February 27th, 2018 • Pharmaceutical preparations • New York

MannKind Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:

Sample 1Sample 2Sample 3See All (363)
MANNKIND CORPORATION and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF [ ], 20
Common Stock Warrant Agreement • March 29th, 2019 • Mannkind Corp • Pharmaceutical preparations • New York

COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between MANNKIND CORPORATION, a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (266)
MANNKIND CORPORATION and , As Warrant Agent FORM OF DEBT SECURITIES WARRANT AGREEMENT Dated As Of MANNKIND CORPORATION Form of Debt Securities Warrant Agreement
Warrant Agreement • April 18th, 2016 • Mannkind Corp • Pharmaceutical preparations • New York

DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between MANNKIND CORPORATION, a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (241)
1. TERM
Executive Severance Agreement • April 30th, 2004 • Mannkind Corp • California
Sample 1Sample 2Sample 3See All (231)
MANNKIND CORPORATION and , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF [ ], 20
Preferred Stock Warrant Agreement • March 29th, 2019 • Mannkind Corp • Pharmaceutical preparations • New York

PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between MANNKIND CORPORATION, a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (199)
MANNKIND CORPORATION and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [ ], 20
Debt Securities Warrant Agreement • March 29th, 2019 • Mannkind Corp • Pharmaceutical preparations • New York

DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between MANNKIND CORPORATION, a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (113)
FORM OF SECURITIES PURCHASE AGREEMENT
Form of Securities Purchase Agreement • April 6th, 2018 • Mannkind Corp • Pharmaceutical preparations • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of April 5, 2018, between MannKind Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

Sample 1Sample 2Sample 3See All (84)
MANNKIND CORPORATION AND U.S. BANK NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of October 30, 2017 5.75% Convertible Senior Subordinated Exchange Notes Due 2021
Mannkind Corp • October 30th, 2017 • Pharmaceutical preparations • New York

INDENTURE dated as of October 30, 2017 between MannKind Corporation, a Delaware corporation, as issuer (the “Company”) and U.S. Bank National Association, as trustee, a national banking association organized under the laws of the United States of America (the “Trustee”).

Sample 1Sample 2Sample 3See All (79)
7,400,000 Shares MannKind Corporation Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • August 10th, 2009 • Mannkind Corp • Pharmaceutical preparations • New York

JEFFERIES & COMPANY, INC. as Representative of the several Underwriters named in Schedule I hereto 520 Madison Avenue New York, New York 10022

Sample 1Sample 2Sample 3See All (48)
MANNKIND CORPORATION AND WELLS FARGO BANK, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of August 10, 2015 5.75% Convertible Senior Subordinated Exchange Notes due 2018
Indenture • August 10th, 2015 • Mannkind Corp • Pharmaceutical preparations • New York

INDENTURE dated as of August 10, 2015 between MannKind Corporation, a Delaware corporation, as issuer (the “Company”) and Wells Fargo Bank, National Association, as trustee, a national banking association organized under the laws of the United States of America (the “Trustee”).

Sample 1Sample 2Sample 3See All (35)
40,000,000 Shares of Common Stock ($0.01 par value per Share) and Warrants to Purchase up to 30,000,000 Shares of Common Stock MannKind Corporation UNDERWRITING AGREEMENT
Underwriting Agreement • October 19th, 2012 • Mannkind Corp • Pharmaceutical preparations

MannKind Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you, Jefferies & Company, Inc. (“Jefferies”) and Piper Jaffray & Co. (“Piper”), acting as representatives (together, the “Representatives”) of the underwriters named on Schedule I to this Agreement (the “Underwriters”), an aggregate of (i) 40,000,000 shares (the “Shares”) of the Company’s common stock, $0.01 par value per share (the “Common Stock”), and (ii) warrants of the Company, in the form set forth in Exhibit F hereto, to purchase 30,000,000 shares of Common Stock (the “Warrants”). Each share of Common Stock is being sold together with a Warrant to purchase 0.75 of a share of Common Stock at an exercise price of $2.60 per share. The shares of Common Stock issuable upon exercise of the Warrants are called the “Warrant Shares,” and the Warrant Shares, together with the Warrants and the Shares, are called the “Securities.” The 40,000,000 Shares to

Sample 1Sample 2Sample 3See All (23)
JOINT FILING AGREEMENT JOINT FILING AGREEMENT
Joint Filing Agreement • January 31st, 2006 • Mannkind Corp • Pharmaceutical preparations

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock, par value $0.01 per share, of MannKind Corporation, and that this Agreement be included as an Exhibit to such joint filing. The Agreement may be executed in any number of counterparts all of which taken together shall constitute one and the same instrument.

Sample 1Sample 2Sample 3See All (23)
MANNKIND CORPORATION Common Stock (par value $0.01 per share) At-The-Market Issuance Sales Agreement
Sales Agreement • March 3rd, 2014 • Mannkind Corp • Pharmaceutical preparations • New York

MannKind Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with MLV & Co. LLC (“MLV”), as follows:

Sample 1Sample 2Sample 3See All (21)
EXHIBIT B
Mannkind Corp • January 31st, 2006 • Pharmaceutical preparations • California
Sample 1Sample 2Sample 3See All (19)
AutoNDA by SimpleDocs
AMENDMENT NO. 7 TO CREDIT AND SECURITY AGREEMENT
Credit and Security Agreement • April 26th, 2021 • Mannkind Corp • Pharmaceutical preparations • New York

This AMENDMENT NO. 7 TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 22nd day of April, 2021, by and among MANNKIND CORPORATION, a Delaware corporation (“MannKind”), MANNKIND LLC, a Delaware limited liability company (“MannKind LLC”), QRUMPHARMA, INC., a Delaware corporation (“QP”, and, QP, together with MannKind and MannKind LLC, each a “Borrower” and collectively, the “Borrowers”), MIDCAP FINANCIAL TRUST, as Agent (in such capacity, together with its successors and assigns, “Agent”) and the financial institutions or other entities from time to time parties to the Credit Agreement referenced below, each as a Lender.

Sample 1Sample 2Sample 3See All (17)
MANNKIND CORPORATION Underwriting Agreement
Mannkind Corp • December 8th, 2006 • Pharmaceutical preparations • New York

MannKind Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to Merrill Lynch & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”) and J.P. Morgan Securities Inc. (“JPMorgan”, together with Merrill Lynch, the “Underwriters”), $100,000,000 aggregate principal amount of its 3.75% Senior Convertible Notes due 2013 (the “Notes”), and with respect to the grant by the Company to the Underwriters, acting severally and jointly, of the option described in Section 2(a) hereof to purchase all or any part of an additional $15,00,000 aggregate principal amount of Notes to cover over-allotments, if any. The aforesaid $100,000,000 principal amount of the Notes to be purchased by the Underwriters (the “Initial Securities”) and all or any part of the $15,000,000 aggregate principal amount of Notes subject to the option described in Section 2(a) hereof (the “Option Securities”) are hereinafter called, collectively, the “Securities.” The Securities will

Sample 1Sample 2Sample 3See All (16)
MANNKIND CORPORATION Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement
Mannkind Corp • April 26th, 2016 • Pharmaceutical preparations • New York

MannKind Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with FBR Capital Markets & Co. (“FBR”), as follows:

Sample 1Sample 2Sample 3See All (11)
MANNKIND CORPORATION AND WELLS FARGO BANK, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of August 24, 2010 5.75% Convertible Senior Notes due 2015
Indenture • August 24th, 2010 • Mannkind Corp • Pharmaceutical preparations • New York

INDENTURE dated as of August 24, 2010 between MannKind Corporation, a Delaware corporation, as issuer (the “Company”) and Wells Fargo Bank, National Association, a national banking association, as trustee (the “Trustee”).

Sample 1Sample 2Sample 3See All (10)
WITNESSETH:
Supply Agreement • February 23rd, 2005 • Mannkind Corp • Pharmaceutical preparations • Delaware
Sample 1Sample 2Sample 3See All (8)
MANNKIND CORPORATION Common Stock (par value $0.01 per share) At-The-Market Issuance Sales Agreement
Common Stock • March 18th, 2013 • Mannkind Corp • Pharmaceutical preparations • New York

MannKind Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with MLV & Co. LLC (“MLV”), as follows:

Sample 1Sample 2Sample 3See All (5)
MannKind Corporation Change of Control Agreement
Change of Control Agreement • October 17th, 2007 • Mannkind Corp • Pharmaceutical preparations • California

This Change of Control Agreement (this “Agreement”), dated and effective as of October 10, 2007 (the “Effective Date”), is between MannKind Corporation, a Delaware corporation (the “Company”), and [Name] (the “Executive”).

Sample 1Sample 2Sample 3See All (4)
MANNKIND CORPORATION 20,000,000 Shares of Common Stock Underwriting Agreement
Mannkind Corp • December 8th, 2006 • Pharmaceutical preparations • New York

MannKind Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 20,000,000 shares of common stock, par value $0.01 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 3,000,000 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares include 5,776,000 shares of common stock, par value $0.01 per share, of the Company (the “Affiliate Shares”) to be purchased by the persons named in Schedule 2 hereto (the “Affiliate Purchasers”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are herein referred to as the “Stock”.

Sample 1Sample 2Sample 3
MANNKIND CORPORATION and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF MANNKIND CORPORATION FORM OF DEBT SECURITIES WARRANT AGREEMENT
Securities Warrant Agreement • August 9th, 2007 • Mannkind Corp • Pharmaceutical preparations • New York

Debt Securities Warrant Agreement, dated as of [ ], between MannKind Corporation, a Delaware corporation (the “COMPANY”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “WARRANT AGENT”).

Sample 1Sample 2Sample 3
EXCHANGE AND EIGHTH AMENDMENT TO FACILITY AGREEMENT
Facility Agreement • July 13th, 2018 • Mannkind Corp • Pharmaceutical preparations • New York

This EXCHANGE AND EIGHTH AMENDMENT TO FACILITY AGREEMENT (this “Agreement”) dated as of July 12, 2018, is by and among MannKind Corporation, a Delaware corporation (the “Borrower”), MannKind LLC, a Delaware limited liability company (the “Guarantor,” and together with the Borrower collectively, the “Obligors”), Deerfield Private Design Fund II, L.P. (“DPDF”) and Deerfield Private Design International II, L.P. (“DPDI” and, together with DPDF, the “Purchasers”). Capitalized terms used herein which are defined in the Facility Agreement (as defined below), unless otherwise defined herein, shall have the meanings ascribed to them in the Facility Agreement.

Sample 1Sample 2Sample 3
MANNKIND CORPORATION AND U.S. BANK NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of August 14, 2015 5.75% Convertible Senior Subordinated Exchange Notes due 2015
Indenture • August 18th, 2015 • Mannkind Corp • Pharmaceutical preparations • New York

INDENTURE dated as of August 14, 2015 between MannKind Corporation, a Delaware corporation, as issuer (the “Company”) and U.S. Bank National Association, as trustee, a national banking association organized under the laws of the United States of America (the “Trustee”).

Sample 1Sample 2Sample 3
EXCHANGE AGREEMENT
Exchange Agreement • July 18th, 2019 • Mannkind Corp • Pharmaceutical preparations • New York

This EXCHANGE AGREEMENT (this “Agreement”) dated as of July 18, 2019, is by and among MannKind Corporation, a Delaware corporation (the “Borrower”), MannKind LLC, a Delaware limited liability company (“Guarantor” and together with the Borrower, collectively, the “Obligors”), Deerfield Private Design Fund II, L.P. (“DPDF”) and Deerfield Private Design International II, L.P. (“DPDI” and, together with DPDF, the “Purchasers”). Capitalized terms used herein which are defined in the Facility Agreement (as defined below), unless otherwise defined herein, shall have the meanings ascribed to them in the Facility Agreement.

Sample 1Sample 2Sample 3
MANNKIND CORPORATION (A Delaware corporation) 9,000,000 Shares of Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • August 24th, 2010 • Mannkind Corp • Pharmaceutical preparations • New York

MannKind Corporation, a Delaware corporation (the “Company”), subject to the terms and conditions stated herein and pursuant to the Share Lending Agreement (the “Share Lending Agreement”), dated August 18, 2010, between the Company and Bank of America, N.A. (the “Borrower”), proposes to issue and lend to the Borrower, an affiliate of Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”), as a share loan pursuant to and upon the terms of the Share Lending Agreement, 9,000,000 shares of Common Stock, par value $0.01 per share, of the Company (“Common Stock”). The aforesaid shares of Common Stock are herein called, collectively, the “Securities.” The Borrower will transfer, or delegate the right to receive (in accordance with the Share Lending Agreement), the borrowed Securities to Merrill Lynch, which will sell the borrowed Securities to the public as an underwriter (the “Underwriter”).

Sample 1Sample 2Sample 3
Time is Money Join Law Insider Premium to draft better contracts faster.